The pressure of the sound waves cause thousands of tiny sensitive hairs in the inner ear to vibrate causing the hair cells to fire tiny electric signals . These electrical signals are then travel to the cochlear nerve of the auditory pathway to the brain. The potassium ion current through a channel in the cell membrane and then from the hair cells. In hearing-impaired persons this potassium channel, a protein molecule as the KCNQ4 is damaged by the mutation.
The discoveries by Matthias Heidenreich and Stefan Lechner of the groups of Thomas Jentsch and Gary Lewin clearly show there are parallels to be heard. Laboratory in Jentsch, investigators first developed a mouse model for deafness by creating a mouse line that has the same mutation in the potassium channel as an individual with DFNA2. Although the defective channel did not kill the touch receptors in the skin, where the KCNQ4 potassium channel found, as it will have in the ear, the touch receptors showed an altered response to the electrical mechanical stimuli in the mouse model.To an open letter addressed that Federal Drug Admin , which seems in the the April issue of the Journal of grafting , of the American Society Transplantation and the American Society of transplantation Surgeons to explain how. FDA politics elimination of transplantation medicine in the U.S. Flavio Vincenti, President of AST and one of the Ask – authors described the letter in an appeal to. Reconsider its policies.
At Vincenti claims that FDA has policy: – lots of transplant centers be discouraged from taking part in clinical trials of new drugs transplantation.
In summary, FDA policy provides the use of immunosuppressive agents in organ transplants clinical studies which are not, over 2,700 outside of the U.S. To find for clinical studies view more the preferred treatment by drug grafts doctors. The letter can by reacting checked.